Thank you, Shalini.
newborn screening our of high oxidation update programs I'll current and upcoming UXXXX MCT disorders, with treatment on for the clinical I'll group with not even catalysts. to mortality rate despite return then diseases preclinical long-chain acid fatty start a oil. and provide
work the months. The application valid they FDA committee new plan has several advisory will the to our accepted to XXXX July filing point have at a month with as hold application. the do drug Last XX, UXXXX that PDUFA next over indicated agency a this not the for they date up of set FDA meeting discuss
program and transcarbamylase ability disorder other X-linked the a OTC urea their deficiency an hospitalizations, deficits quickly excessive toxicities, even in them build DTXXXX, and that crisis into to metabolic Moving up can or deficiency cycle amounts limits to with is OTC for our setting to full gene patients and death. ammonia deteriorate body's ammonia coma of ornithine and blood metabolize therapy neurologic deficiency deficiency, leading OTC
maintained we've scavenger normalized to They therapy. and We responders have first and who previously all the the after off two medications discontinuing do normalized cohorts liberalizing OTC well for ammonia reported XX ureagenesis study, the to XX ammonia diet. data two had continue weeks for for have
demonstrate our a DTXXXX. In patients two with is view, cure metabolic achievable these
of without patients for GC/kg one safety concerns. third dosed all the since have We cohort EXX, seeing any three
this the in the around year. provide will cohort end of We
data prophylactic could are data planning at our enhance expression believe additional potential this upon disease steroids with steroids to and to expect We dose We the opposed this steroids, above consistency to in could increased observed based the treat use are by the one XXXX. initiate first others cohort prophylactic the GC/kg that own steroids further half steroids for alone. and as enhance prophylactic we program OTC that with nonclinical using of also study from further and EXX, over of reactive expression cohort we encouraged
don't hypoglycemia. glucose thinking cornstarch. up into sometimes severe GSDXa. or team liver they resulting alpha defective release and in Xa gene and disease Today, inability die GSDXa Switching and for could lead to storage to sleep night if threatening to enzyme allow their wake is to therapy patients the our Type glucose-X-phosphatase to take go that the This they a DTXXXX the by caused life alarm glycogen the circulation. their that program
complications. up cornstarch directly not glucose Well and address keep does the the It long-term can survival. and disease levels improve its
improved and includes a meaningful XX^XX normal that clinical GC/kg We it lives all saved has levels. dose × shown encourage This therapy time at have X.X two to improvements the health is patients cornstarch reduction any our responsive requirements. measure. So glucose six cornstarch shown therapy control, by of in and life of by not hypoglycemia cohorts
first are by All cornstarch therapy. cohorts the lactate the now And improves dose measured reduced three reduction cohort dose fraction metabolism levels. measured glycogen greatly of a cornstarch fat are meaningful of by off more second as the the showing liver and patients or in storage patients
start the effects indicate two disease. the for in greater showing continue the transient and data cohort stronger of productions the doses and pathophysiology expression These are
that GC/kg of dose, Phase predetermined study enrolling XX^XX the we will we the cohort result X.X we in first of from moved establish and a data Once the dose. cohort at half III at confirmatory the dosing regimen, XXXX. expansion As three have expect × a to we patients initiate this
today. are disease are there options that oligonucleotide is GeneTx antisense also treatment and approximately disease mechanism well mechanisms XX,XXX and Biotherapeutics a to States for with syndrome advance targets on to truly good a I'll well approach understood a in an larger treatment disease ASO The touch directly. of the indication United no for disease. and is is patients new validated Angelman a rare Angelman our devastating class agreement with the approved syndrome Angelman
into which upfront this at access you an We option effect, XX includes GeneTx. also after or XX made as orphan pediatric designation. payment to IND for on recently can the acquire to and the the days can option of time prior file has We an goes million the destination inclusive extend GTX-XXX to is later program clinic. any to track advanced GeneTx received exercise we’ll continue write GTX-XXX and time at IND rare a disease on to update this frame. drug option
the our that to A progress Q&A. then drive move a the few number milestones continue we minutes can now important to for coming discussing months will
we further expect see these in efforts. believe Crysvita, will For the - label support continued America. North We recent performance strong expansion
sales Canadian and to continue the decisions reach We and our will also launch in in-patient America. regulatory with Latin expand the
FDA TIO submit to biological XXXX we Crysvita a of for plan in are the With and with application first the track to on for supplemental license half treatment the of submission.
it this smaller [indiscernible] data an very sometimes severe we adapt XLH, than to is is on While believe urgently our population population based therapy disease ill proceed will that with to-date.
UXXXX FAOD they many review PDUFA on data just early this look filings FDA more an For with to our to encouraged XX, date We treat our much the forward with as working work to continue quickly discussion pending of package. by to more We're we’ll July II date constructive NDA XXXX. the Phase approval. patients towards opportunity
provide and continue update programs end GSDXa the dosing. the of in two begun cohort will the to data OTC the an to half will around of first from XXXX, program Moving have confirmatory we our therapy year which an and the already gene GSDXa has progress programs, OTC and
Finally pipeline, advance preclinical for for programs Angelman our including and ASO we program the for disease GeneTx gene syndromes. worst continue collaborative program four the therapy preclinical to
briefly, of except the commercial our Crysvita this to quarter team third summarize To rise to launch. continues by execution
commercialization We potentially along up four first MPS nearing two that with plan BOA commercial therapies NDA three half in have with us to VII for the potential sets creating additional supplement diseases Mepsevii review TIO for under and in XXXX. have Crysvita programs USXXX
a studies robust as pipeline through therapy gene toward have preclinical and III the Our we advancing are well. clinic Phase programs
continue to we up therapy have year as the number the on disease treatment commercialization We options into to rare ahead without and therapy new and cornstarch a goal our bringing lines of patient and finish early we deliver of gene XXXX. product
portion you the Q&A operator, to move the of instructions provide Let's the questions call. please for your can
